XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Parties Transactions (Tables)
3 Months Ended
Mar. 31, 2024
Related Parties Transactions [Abstract]  
Schedule of Related Parties of the Company with whom Transactions The related parties of the Company with whom transactions are reported in these financial statements are as follows:
Name of entity or Individual   Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)   Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)   100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)   Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
YuanGene Corporation (the “YuanGene”)   Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”)   Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Keypoint Technology Ltd. (the “Keypoint’)   The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”)   Shareholder of the Company
Yoshinobu Odaira (the “Odaira”)   Director of the Company
GenePharm Inc. (the “GenePharm”)   Dr. George Lee, Board Director of BioKey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”)   Shareholder of the Company
LBG USA, Inc. (the “LBG USA”)   100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”)   Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”)   Shareholder of the Company
The Jiangs   Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company; the Chairman of Rgene; the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst
 
Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.
 
Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.
 
Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.
 
Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Zhewei Xu   Shareholder of the Company
BioHopeKing Corporation   Entity controlled by controlling beneficiary shareholder of ABVC
Jaimes Vargas Russman     CEO of AiBtl BioPharma Inc
Amkey Ventures, LLC (“Amkey”)   An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan   Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation   Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited   An entity 100% owned by Mr. Tsung-Shann Jiang
Schedule of Accounts Receivable Due From Related Parties Accounts receivable due from related parties consisted of the following as of the periods indicated:
   March 31,   December 31, 
   2024   2023 
   (Unaudited)     
 Rgene  $10,463   $10,463 
Total  $10,463   $10,463 

 

Schedule of Due From Related Parties - Current Due from related–party - Current
   March 31,   December 31, 
   2024   2023 
   (Unaudited)     
Rgene  $541,372   $541,486 
BioFirst   346,565    206,087 
Total  $887,937   $747,573 
Schedule of Due From Related Parties - Non Current Due from related parties – Non-Current
   March 31,   December 31, 
   2024   2023 
BioFirst (Australia)  $839,983   $839,983 
BioHopeKing Corporation   123,363    113,516 
Total   963,346    953,499 
Less: allowance for expected credit losses accounts   (839,983)   (839,983)
Net  $123,363   $113,516 
Schedule of Amount Due to Related Parties Amount due to related parties consisted of the following as of the periods indicated:
   March 31,   December 31, 
   2024   2023 
   (Unaudited)     
The Jiangs  $152,501   $19,789 
Due to shareholders   145,858    152,382 
Due to a Director   3,613    961 
 Total  $301,972   $173,132